Zydus Ties Up With Synthon for MS Drug in US
ECONOMY & POLICY

Zydus Ties Up With Synthon for MS Drug in US

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).
The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.
As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.
“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.
The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.
This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Zydus Lifesciences Ltd announced on Thursday that its subsidiary has signed an exclusive licensing and supply agreement with Netherlands-based Synthon BV to introduce a generic version of Ozanimod capsules in the United States for the treatment of relapsing forms of multiple sclerosis (MS).The drug is the generic equivalent of ZEPOSIA, a therapy used in managing various relapsing MS conditions. The agreement was disclosed through a regulatory filing.As per the arrangement, Synthon BV will take on the responsibility for securing final regulatory approval from the US Food and Drug Administration (FDA), followed by the manufacture and supply of the capsules. Zydus, through its US subsidiary, will oversee commercialisation across the American market.“This collaboration with Synthon enables us to bring this important treatment to the US market,” said Punit Patel, President and CEO of Zydus Pharmaceuticals (USA) Inc.The total addressable market for Ozanimod capsules in the US is estimated at USD 637 million (approximately Rs 53.1 billion), according to IQVIA MAT data as of July 2025.This strategic move strengthens Zydus Lifesciences’ presence in the neurology space and further expands its portfolio of complex generics in the US pharmaceutical market. 

Next Story
Real Estate

Hiranandani Launches India’s Largest Coastal Township in Alibaug

Hiranandani Communities, led by Dr Niranjan Hiranandani, has launched Hiranandani Sands, India’s largest integrated coastal township, near Mumbai in Alibaug, with an estimated revenue of Rs 170 billion. Spanning 225 acre, the township is designed as Mumbai’s lifestyle extension hub, featuring luxury homes, signature villas, plotted developments, and branded serviced apartments. Residents will have private beachfront access and a jetty, alongside five hotels covering luxury, business, and leisure segments, a mega convention centre, eco-wellness hub, beachside entertainment, and a globa..

Next Story
Real Estate

TDI City Kundli Relaunched with Rs 1 Billion Redevelopment Plan

TDI Infrastructure has announced a Rs 1 billion investment to redevelop and relaunch the 1,100-acre TDI City Kundli, positioning it as a natural and affordable alternative for residents of North and West Delhi. Situated just 30 minutes from Delhi via the newly operational UER-2, the township currently has around 7,000 plot owners and more than 5,000 apartments.“As part of the redevelopment, we are collaborating with Resident Welfare Associations (RWAs) to upgrade 62 parks across 23 acres, improve internal roads, enhance the existing clubhouse, and commence a new second clubhouse to support r..

Next Story
Infrastructure Transport

India Plans Rs 70 Billion Push for Shipbuilding and Ports

The Indian government is preparing a Rs 70 billion stimulus for the shipping sector, with the Union Cabinet expected to review three major schemes shortly, according to media reports. The initiative reflects India’s efforts to expand shipbuilding, port infrastructure, and maritime trade capacity in the coming years.Shares of leading shipbuilders such as Shipping Corporation of India (SCI), Garden Reach Shipbuilders & Engineers (GRSE), and Mazagon Dock Shipbuilders have already risen on expectations of government support.The plan centres on three key initiatives: a Rs 20 billion Shipbuild..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?